Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06923072 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
Minor3 versionsRe-verified since Feb 25, 2026, no change to tracked fieldsv192-v194
MinorStart date changed from estimate of Feb 25, 2026 to Feb 18, 2026v191
MinorStart date: Feb 24, 2026 to Feb 25, 2026v190
Show 43 earlier versionsHide 43 earlier versions
MinorStart date: Feb 23, 2026 to Feb 24, 2026v189
MinorStart date: Feb 22, 2026 to Feb 23, 2026v188
MinorStart date: Feb 9, 2026 to Feb 22, 2026v187
MinorStart date: Feb 3, 2026 to Feb 9, 2026v186
MinorStart date: Feb 2, 2026 to Feb 3, 2026v185
MinorStart date: Feb 1, 2026 to Feb 2, 2026v184
MinorStart date: Jan 29, 2026 to Feb 1, 2026v183
MinorStart date: Jan 28, 2026 to Jan 29, 2026v182
MinorStart date: Jan 27, 2026 to Jan 28, 2026v181
MinorStart date: Jan 26, 2026 to Jan 27, 2026v180
MinorStart date: Jan 22, 2026 to Jan 26, 2026v179
MinorStart date: Jan 21, 2026 to Jan 22, 2026v178
MinorStart date: Jan 20, 2026 to Jan 21, 2026v177
MinorStart date: Jan 19, 2026 to Jan 20, 2026v176
MinorStart date: Jan 18, 2026 to Jan 19, 2026v175
MinorStart date: Jan 15, 2026 to Jan 18, 2026v174
MinorStart date: Jan 14, 2026 to Jan 15, 2026v173
MinorStart date: Jan 13, 2026 to Jan 14, 2026v172
MinorStart date: Jan 12, 2026 to Jan 13, 2026v171
MinorStart date: Jan 11, 2026 to Jan 12, 2026v170
MinorStart date: Jan 8, 2026 to Jan 11, 2026v169
MinorStart date: Jan 6, 2026 to Jan 8, 2026v168
MinorStart date: Jan 5, 2026 to Jan 6, 2026v167
MinorStart date: Jan 4, 2026 to Jan 5, 2026v166
MinorStart date: Jan 1, 2026 to Jan 4, 2026v165
MinorStart date: Dec 30, 2025 to Jan 1, 2026v164
MinorStart date: Dec 29, 2025 to Dec 30, 2025v163
MinorStart date: Dec 28, 2025 to Dec 29, 2025v162
MinorStart date: Dec 25, 2025 to Dec 28, 2025v161
MinorStart date: Dec 24, 2025 to Dec 25, 2025v160
MinorStart date: Dec 23, 2025 to Dec 24, 2025v159
MinorStart date: Dec 22, 2025 to Dec 23, 2025v158
MinorStart date: Dec 21, 2025 to Dec 22, 2025v157
MinorStart date: Dec 18, 2025 to Dec 21, 2025v156
MinorStart date: Dec 16, 2025 to Dec 18, 2025v155
MinorStart date: Dec 15, 2025 to Dec 16, 2025v154
MinorStart date: Dec 14, 2025 to Dec 15, 2025v153
MinorStart date: Dec 11, 2025 to Dec 14, 2025v152
MinorStart date: Dec 10, 2025 to Dec 11, 2025v151
MinorStart date: Dec 9, 2025 to Dec 10, 2025v150
MinorStart date: Dec 8, 2025 to Dec 9, 2025v149
MinorStart date: Dec 7, 2025 to Dec 8, 2025v148
MinorStart date: Dec 3, 2025 to Dec 7, 2025v147
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Background:
Kohlmeier-Degos (KD) is a rare disease that causes inflammation and blood clots, leading to blockages in small blood vessels. These blockages can result in K-D lesions throughout the body, affecting the skin, lungs, heart, spinal cord, and brain. KD can be fatal. No treatment exists for this disease.
Objective:
To test a study drug (baricitinib) in people with brain and spine lesions caused by KD disease. Baricitinib is FDA approved to treat other disorders but has not yet been tried in people with KD.
Eligibility:
People aged 18 years or older with KD-related lesions in the brain and spine.
Design:
Participants will be screened; they will have a physical exam with blood tests. They will also have a baseline visit that may include multiple tests, such as imaging scans of the brain and spine; a lumbar puncture to collect fluid from the spinal canal; and a meeting with a neurologist. They will fill out a questionnaire about their health. They will continue to take their normal medications throughout the study.
Baricitinib is a tablet taken by mouth. Participants will remain on their normal medications for 12 weeks after their baseline visit. Then they will also take the study drug once a day at home for 24 weeks.
Participants will have clinic visits every few weeks for up to 40 weeks. Some visits may take 1 to 4 days. Baseline tests will be repeated 3 more times during study visits. Other visits will require only blood tests; these may be done by local labs that will send the samples to NIH; 2 visits may be done via telehealth....